THOR Synthorx Inc

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Reardon Tighe	2. Issuer Name and Ticker or Trading Symbol Synthorx, Inc. [ THOR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Acting Chief Financial Officer
(Last)          (First)          (Middle) C/O SYNTHORX, INC., 11099 N. TORREY PINES ROAD, SUITE 190	3. Date of Earliest Transaction (MM/DD/YYYY) 1/23/2020
(Street) LA JOLLA, CA 92037 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	1/23/2020		U		43688	D	$68.00	0	D
Common Stock	1/23/2020		U		1682086	D	$68.00	0	I	By Avalon X SPV I, L.P. (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.64	1/23/2020		D			18723	(2)	8/29/2028	Common Stock	18723	$63.36	0	D
Employee Stock Option (right to buy)	$11.00	1/23/2020		D			30000	(3)	12/5/2028	Common Stock	30000	$57.00	0	D

Explanation of Responses:
(1)	The Reporting Person is Chief Financial Officer and Partner of Avalon X SPV GP LLC, general partner of Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.
(2)	This option, which was immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,186,289.28, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
(3)	This option, which provided for vesting of 100% of the shares subject to the option upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Reardon Tighe C/O SYNTHORX, INC. 11099 N. TORREY PINES ROAD, SUITE 190 LA JOLLA, CA 92037			Acting Chief Financial Officer

Signatures
/s/ Christian V. Kuhlen, Attorney-in-Fact		1/24/2020
**Signature of Reporting Person		Date